Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nebius Group NV — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Nebius Group NV trades at $212.23 (market cap $55.77B). The key difference: Nebius Group NV is the larger of the two by market cap, and Nebius Group NV is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NBIS | |
|---|---|---|
Market Cap | $39.89B | $55.77B |
Sector | Health | Technology |
52-Week High | $491.22 | $286.69 |
52-Week Low | $278.09 | $44.30 |
Enterprise Value | $38.15B | $55.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NBIS trades at $219.65, up 1.6% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $529.80 million in 2025 with a net income of $82.50 million, and analyst consensus is strongly bullish with an average price target of $248.00. Recent news highlights aggressive AI infrastructure expansion and partnerships, though volatility persists amid sector competition fears.
Outlook remains positive given strong analyst buy ratings and projected revenue growth to $878 million in 2026, but high valuation multiples and competitive threats from tech giants like Meta pose significant risks. Cash flow trends show heavy investing activity funded by financing, supporting growth but elevating leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
